';
Featured
Featured posts

The Office of Children, Youth, and Families (OCYF) is continuing to offer free Trauma Intensive Courses to support individuals and teams in their professional development. These courses provide essential training in trauma awareness and healing. Options include Train-the-Trainer Sessions and sessions on processing pain as well as facilitating healing. Participants can deepen their understanding and skills in trauma-informed care, with limited seats available. To register for these courses, visit the course registration page. Additionally, various trauma-related workshops are open for registration, covering different aspects of trauma. For more information, visit the Lakeside Global Institute — Trauma Workshops 2024 page.

RCPA attended the Office of Mental Health and Substance Abuse Services (OMHSAS) telehealth webinar on Monday, January 29, alongside many provider members, regarding the Federal payment conditions related to the delivery of telehealth services and the requirement that the physicians or clinicians must present in the office, or that the client must be in the office during the telehealth session, to meet the guideline. It was explained that despite the standards outlined in the current OMHSAS Telebehavioral Health Bulletin, under the Federal “4 walls” statute, this is a required Federal Medicaid payment condition. These requirements cannot be waived.

The purpose of today’s call was twofold: explaining the “4 walls” requirements, and for providers to give vital feedback to OMHSAS on the impacts, challenges, and barriers to accessing services that this may create for consumers and families. This Medicaid standard remains in effect, and RCPA recommends provider members review their operating practices to ensure compliance.

During this time, RCPA will continue its efforts and work with OMHSAS, the HealthChoices partners, and stakeholders to ensure access to services via telehealth. You can review today’s OMHSAS telehealth webinar slide deck. We are also looking to obtain a recording of the webinar to share with our members.

If you have questions, please contact RCPA Policy Director Jim Sharp. The next RCPA Telehealth Operations Committee meeting is scheduled for Tuesday, February 27; however, we will be reviewing if we need to meet sooner based on current information.

Please share this information with your stakeholder networks.

RCPA is delighted to share our 2023 Year in Review! We’re confident that this review will provide you with valuable insights, and inspire you as we highlight some of our significant achievements. This past year, we have embarked on groundbreaking initiatives and celebrated remarkable successes, all thanks to our collective efforts. As we step into 2024, we remain optimistic about reaching new heights together, and hope this review fuels your enthusiasm for what we can all accomplish in the coming year.

0 1441

There is a request from an RCPA member who is looking to revise some policies and job descriptions for their organization. Please contact Fred Serino, Director of Human Resources at Vista Autism Services, if you are willing to share the following policies/job descriptions from your organization:

  • Inclement weather policy;
  • Evaluation form and process; and/or
  • Job description for Director of QA/QI.

In addition to this request, you can also view and share information, as well as post questions, on the RCPA website under the HR Forum. Please access the online forum under the Human Resources drop-down menu at the top of the RCPA website (note that you must be logged in with your RCPA member website account). If you do not have access, please request access here. Contact Sharon Militello if you have questions concerning the HR forum.

We thank you for your assistance with this request.

The Office of Developmental Programs (ODP) has shared this important announcement from the U.S. Food and Drug Administration (FDA) about a recall of two cough medicine products by Robitussin. The products are Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult. Please see the specific Lot Numbers below that are involved in the recall.  If you have one of these products with the matching Lot Number, stop use immediately and contact your health care provider.


Haleon Issues Voluntary Nationwide Recall of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult Products Due to Microbial Contamination

Summary
Company Announcement Date: January 24, 2024
FDA Publish Date: January 24, 2024
Product Type: Drugs
Reason for Announcement: Microbial Contamination
Company Name: Haleon
Brand Name: Robitussin
Product Description: Cough syrups

Haleon is voluntarily recalling eight lots of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult to the consumer level. The product is being recalled due to microbial contamination.

In immunocompromised individuals, the use of the affected product could potentially result in severe or life-threatening adverse events, such as fungemia or disseminated fungal infection. In non-immunocompromised consumers, the population most likely to use the product, life-threatening infections are not likely to occur. However, the occurrence of an infection that may necessitate medical intervention cannot be completely ruled out. To date, Haleon has not received any reports of adverse events related to this recall.

Robitussin Honey CF Max Day and Nighttime are cough syrups indicated for the temporary relief of symptoms occurring with cold or flu, hay fever, or other respiratory allergies. This recall covers only the following lots:

Product Lot Number Expiry Date
ROBITUSSIN HONEY CF MAX
DAY ADULT 4OZ
T10810 31OCT2025
ROBITUSSIN HONEY CF MAX
DAY ADULT 8OZ
T08730
T08731
T08732
T08733
T10808
31MAY2025
31MAY2025
31MAY2025
31MAY2025
30SEP2025
ROBITUSSIN HONEY CF MAX
NT ADULT 8OZ
T08740 T08742 30JUN2026
30JUN2026

Haleon is notifying its distributors and customers directly and has provided them with instructions for the return of all recalled products. Consumers that have purchased the product listed should stop consumption immediately. Please call our Consumer Relations team at +1-800-245-1040 (Monday through Friday 8:00 am – 6:00 pm Eastern Time) or reach out via email.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

  • Complete and submit the report online
  • Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.